Thoracic Surgery Grand Rounds
May 20, 2015
Long-term survival following open versus VATS lobectomy after induction therapy for non-small cell lung cancer
Zhifei (Jeff) Sun, MD
Impact of patient selection and treatment strategies on outcomes after lobectomy for biopsy-proven stage IIIA PN2 non-small cell lung cancer
Jeff Yang, MD
Performing sublobar resection instead of lobectomy compromises the survival of stage I non-small cell lung cancer patients 80 years of age and older
Brian Gulack, MD
Presenter disclosure of financial relationships: Drs. Yang and Gulack indicate no financial relationships relative to the content presented and no personal/financial relationships to disclose which are relative to this activity.
Dr. D’Amico has no personal/financial relationships to disclose which are relative to this activity. Dr. D'Amico indicates serving as a consultant with Scanlan.
Global Learning Objectives:
1. Review and discuss technical aspects of cardiothoracic surgery.
2. Discuss clinical research findings and advances in thoracic surgery.
3. Present and discuss case studies, protocols and treatment guidelines
as appropriate to the thoracic surgery practice.
RSS Activity Medical Director(s) Disclosure: Dr. Thomas D’Amico has no personal/financial relationships to disclose which are relative to this activity. Dr. D'Amico indicates serving as a consultant with Scanlan.
The Duke University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
---Unapproved Use Disclosure---
Duke School of Medicine requires CME faculty (speakers) to disclose to the attendees: 1) When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (Not FDA approved) ; and 2) Any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and /or unsupported opinion. Faculty at this event may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education, and is not intended to promote off-label use of these medications. If you have any questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
The Duke University School Of Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in this activity.